476 related articles for article (PubMed ID: 10660497)
1. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.
Piddock LJ; Williams KJ; Ricci V
J Antimicrob Chemother; 2000 Feb; 45(2):159-65. PubMed ID: 10660497
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of KRM-1648 by Mycobacterium aurum and Mycobacterium tuberculosis.
Piddock LJ; Ricci V
J Antimicrob Chemother; 2000 May; 45(5):681-4. PubMed ID: 10797093
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis.
Williams KJ; Chung GA; Piddock LJ
Antimicrob Agents Chemother; 1998 Apr; 42(4):795-800. PubMed ID: 9559785
[TBL] [Abstract][Full Text] [Related]
4. Secondary metabolites from Tetracera potatoria stem bark with anti-mycobacterial activity.
Fomogne-Fodjo MC; Ndinteh DT; Olivier DK; Kempgens P; van Vuuren S; Krause RW
J Ethnopharmacol; 2017 Jan; 195():238-245. PubMed ID: 27864111
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
Lu T; Drlica K
J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mycobacterial growth by plumbagin derivatives.
Mathew R; Kruthiventi AK; Prasad JV; Kumar SP; Srinu G; Chatterji D
Chem Biol Drug Des; 2010 Jul; 76(1):34-42. PubMed ID: 20456370
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of nitroxyl donors' effect on mycobacteria.
Galizia J; Acosta MP; Urdániz E; Martí MA; Piuri M
Tuberculosis (Edinb); 2018 Mar; 109():35-40. PubMed ID: 29559119
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.
Altaf M; Miller CH; Bellows DS; O'Toole R
Tuberculosis (Edinb); 2010 Nov; 90(6):333-7. PubMed ID: 20933470
[TBL] [Abstract][Full Text] [Related]
9. Nonquaternary poly(diallylammonium) polymers with different amine structure and their biocidal effect on Mycobacterium tuberculosis and Mycobacterium smegmatis.
Timofeeva LM; Kleshcheva NA; Shleeva MO; Filatova MP; Simonova YA; Ermakov YA; Kaprelyants AS
Appl Microbiol Biotechnol; 2015 Mar; 99(6):2557-71. PubMed ID: 25557627
[TBL] [Abstract][Full Text] [Related]
10. Potentiating the Anti-Tuberculosis Efficacy of Peptide Nucleic Acids through Combinations with Permeabilizing Drugs.
Cotta KB; Ghosh S; Mehra S
Microbiol Spectr; 2022 Feb; 10(1):e0126221. PubMed ID: 35171048
[TBL] [Abstract][Full Text] [Related]
11. [Sensitivity of M. tuberculosis and atypical mycobacteria to ethambutol, capreomycin and rifampicin].
Schröder KH; Hensel J; Scheuch V
Prax Pneumol; 1969 Oct; 23(10):683-94. PubMed ID: 4984409
[No Abstract] [Full Text] [Related]
12. Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus.
Williams KJ; Piddock LJ
J Antimicrob Chemother; 1998 Nov; 42(5):597-603. PubMed ID: 9848443
[TBL] [Abstract][Full Text] [Related]
13. The Mycobacterial Efflux Pump EfpA Can Induce High Drug Tolerance to Many Antituberculosis Drugs, Including Moxifloxacin, in Mycobacterium smegmatis.
Rai D; Mehra S
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0026221. PubMed ID: 34424047
[TBL] [Abstract][Full Text] [Related]
14. Farnesol, a potential efflux pump inhibitor in Mycobacterium smegmatis.
Jin J; Zhang JY; Guo N; Sheng H; Li L; Liang JC; Wang XL; Li Y; Liu MY; Wu XP; Yu L
Molecules; 2010 Oct; 15(11):7750-62. PubMed ID: 21042264
[TBL] [Abstract][Full Text] [Related]
15.
Swaminath S; Paul A; Pradhan A; Sebastian J; Nair RR; Ajitkumar P
Microbiology (Reading); 2020 Feb; 166(2):180-198. PubMed ID: 31746727
[TBL] [Abstract][Full Text] [Related]
16. Use of Mycobacterium smegmatis deficient in ADP-ribosyltransferase as surrogate for Mycobacterium tuberculosis in drug testing and mutation analysis.
Agrawal P; Miryala S; Varshney U
PLoS One; 2015; 10(4):e0122076. PubMed ID: 25874691
[TBL] [Abstract][Full Text] [Related]
17. mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis.
Pasca MR; Guglierame P; De Rossi E; Zara F; Riccardi G
Antimicrob Agents Chemother; 2005 Nov; 49(11):4775-7. PubMed ID: 16251328
[TBL] [Abstract][Full Text] [Related]
18. Flavonoids as Novel Efflux Pump Inhibitors and Antimicrobials Against Both Environmental and Pathogenic Intracellular Mycobacterial Species.
Solnier J; Martin L; Bhakta S; Bucar F
Molecules; 2020 Feb; 25(3):. PubMed ID: 32046221
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis.
Chaturvedi V; Dwivedi N; Tripathi RP; Sinha S
J Gen Appl Microbiol; 2007 Dec; 53(6):333-7. PubMed ID: 18187888
[TBL] [Abstract][Full Text] [Related]
20. Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance.
Rodrigues L; Ramos J; Couto I; Amaral L; Viveiros M
BMC Microbiol; 2011 Feb; 11():35. PubMed ID: 21332993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
